评价贝伐珠单抗联合新辅助放化疗在局部进展期 直肠癌治疗中的可行性和安全性

赵 婷婷, 姬发 祥*
青海大学附属医院肿瘤内科一病区

摘要


目的：分析贝伐珠单抗在局部进展期直肠癌患者的新辅助治疗中的可行性和安全性，为临床诊疗提供参考，
并为进一步研究探索提供方向。方法：检索并查阅近年来国内外医学数据库（PubMed、EMBASE、Cochrane Library、
维普数据库、中国知网、万方数据库等），对局部进展期直肠癌新辅助联合治疗的相关文献进行综述。结论：贝伐珠
单抗在LARC术前治疗中的初步结果既有希望也有陷阱。总体而言，贝伐珠单抗在局部进展期直肠癌患者的新辅助
治疗是可行的，但是围手术期并发症略有增加引起了一些担忧。就pCR而言，联合治疗似乎仅获得了轻微的益处，
因此，将贝伐珠单抗纳入新辅助治疗的方案有待进一步研究。

关键词


局部进展期直肠癌；贝伐珠单抗；新辅助治疗；放疗；化疗

全文:

PDF


参考


[1] 练 磊， 兰 平 . 国 家 卫 健 委 中 国 结 直 肠 癌 诊 疗

规 范 解 读（2020 版 ） —— 外 科 部 分 [J]. 临 床 外 科 杂

志，2021，29（1）：10-12. doi：10.3969/j.issn.1005-

6483.2021.01.004.

[2]Nakayama I, Hirota T, Shinozaki E. BRAF mutation

in colorectal cancers: from prognostic marker to targetable

mutation[J]. Cancers, 2020, 12(11):3236. doi:10.3390/

cancers12113236.

[3] 刘清安，肖泽民，刘晓华，等 . 新辅助化疗结合

三维适形放疗在晚期不可手术切除直肠癌转化治疗中的

应 用 [J]. 中 国 普 通 外 科 杂 志，2016，25（2）：271-275.

doi：10.3978/j.issn.10056947.2016.02.019.

[4] 费 拉 拉，N. ∙ Gerber，HP∙ LeCouter，J.Biology of

VEGF and its receptors.National Medicine. 2003; 9：669-676

[5] 费 拉 拉，N. ∙ Hillan，KJ ∙ Gerber，HP ...Discovery

and development of bevacizumab, an anti-VEGF antibody for

the treatment of cancerNat Rev Drug Discov.2004; 3：391-400

[6]Ye W.The complexity of translating anti-angiogenic

therapies from basic science to the clinic.Development

unit. 2016; 37：114-125

[7]Kerbel RS. Tumor angiogenesis. N Engl J

Med. 2008;358:2039-2049.[8]Willett CG, Kozin SV, Duda DG, di Tomaso E,

Kozak KR, Boucher Y, Jain RK. Combined vascular

endothelial growth factor-targeted therapy and radiotherapy

for rectal cancer: theory and clinical practice. Semin

Oncol. 2006;33:S35-S40.

[9]Willett CG, Boucher Y, di Tomaso E, Duda DG,

Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin

SV, et al. Direct evidence that the VEGF-specific antibody

bevacizumab has antivascular effects in human rectal

cancer. Nat Med. 2004;10:145-147.

[10]Willett CG, Boucher Y, Duda DG, di Tomaso E,

Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung

DC, et al. Surrogate markers for antiangiogenic therapy and

dose-limiting toxicities for bevacizumab with radiation and

chemotherapy: continued experience of a phase I trial in rectal

cancer patients. J Clin Oncol. 2005;23:8136-8139.

[11]Velenik V, Ocvirk J, Music M, Bracko M, Anderluh

F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M.

Neoadjuvant capecitabine, radiotherapy, and bevacizumab

(CRAB) in locally advanced rectal cancer: results of an openlabel phase II study. Radiat Oncol. 2011;6:105.

[ 1 2 ] D w o r a k O , K e i l h o l z L , H o f f m a n n A .

Pathological features of rectal cancer after preoperative

radiochemotherapy. Int J Colorectal Dis. 1997;12:19-23.

[13]Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T,

Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, et al.

A phase II study of neoadjuvant bevacizumab plus capecitabine

and concomitant radiotherapy in patients with locally advanced

rectal cancer. Angiogenesis. 2012;15:141-150.

[14]García, Margarita et al. “Phase II study of

preoperative bevacizumab, capecitabine and radiotherapy for

resectable locally-advanced rectal cancer.”BMC cancer vol.

15 59. 26 Feb. 2015, doi:10.1186/s12885-015-1052-0.

[15]Dellas K, Höhler T, Reese T, Würschmidt F, Engel

E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J. Phase

II trial of preoperative radiochemotherapy with concurrent

bevacizumab, capecitabine and oxaliplatin in patients with

locally advanced rectal cancer. Radiat Oncol. 2013;8:90.

[16]Landry JC, Feng Y, Cohen SJ, Staley CA, Whittington

R, Sigurdson ER, Nimeiri H, Verma U, Prabhu RS, Benson

AB. Phase 2 study of preoperative radiation with concurrent

capecitabine, oxaliplatin, and bevacizumab followed by surgery

and postoperative 5-fluorouracil, leucovorin, oxaliplatin

(FOLFOX), and bevacizumab in patients with locally advanced

rectal cancer: ECOG 3204. Cancer. 2013;119:1521-1527.

[17]Yu, Xin et al. “Neoadjuvant oxaliplatin and

capecitabine combined with bevacizumab plus radiotherapy

for locally advanced rectal cancer: results of a singleinstitute phase II study.”Cancer communications (London,

England) vol. 38,1 24. 21 May. 2018, doi:10.1186/s40880-

018-0294-z.

[18]Nogué M, Salud A, Vicente P, Arriví A, Roca JM,

Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, et al. Addition

of bevacizumab to XELOX induction therapy plus concomitant

capecitabine-based chemoradiotherapy in magnetic resonance

imaging-defined poor-prognosis locally advanced rectal

cancer: the AVACROSS study. Oncologist. 2011;16:614-620.

[19]Eisterer W, Piringer G, DE Vries A, Öfner D, Greil

R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler

J; Austrian Breast and Colorectal Cancer Study Group.

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and

Bevacizumab Followed by Concomitant Chemoradiation and

Surgical Resection in Locally Advanced Rectal Cancer with

High Risk of Recurrence - A Phase II Study. Anticancer Res.

2017 May;37(5):2683-2691. doi: 10.21873/anticanres.11617.

PMID: 28476845.75;PMCID：PMC4342871.


Refbacks

  • 当前没有refback。